GRIFOLS traded at 9.20 this Thursday April 2nd, decreasing 0.07 or 0.71 percent since the previous trading session. Looking back, over the last four weeks, GRIFOLS lost 7.70 percent. Over the last 12 months, its price rose by 9.99 percent. Looking ahead, we forecast GRIFOLS to be priced at 8.47 by the end of this quarter and at 7.76 in one year, according to Trading Economics global macro models projections and analysts expectations.
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.